Compare Stocks → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:DVCRNASDAQ:NVNONASDAQ:SLSNASDAQ:TIL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVCRDiversicare Healthcare Services$10.09+1.0%$10.09$2.50▼$10.09$70.12M0.8618,931 shs49,400 shsNVNOenVVeno Medical$5.01+1.6%$5.14$2.51▼$6.97$66.78M1.1100,927 shs40,200 shsSLSSELLAS Life Sciences Group$1.40+3.7%$1.32$0.50▼$1.91$80.86M2.261.45 million shs438,800 shsTILInstil Bio$11.04-1.8%$11.08$6.07▼$12.98$71.76M1.1722,981 shs13,400 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVCRDiversicare Healthcare Services0.00%0.00%0.00%0.00%0.00%NVNOenVVeno Medical0.00%+0.40%-3.28%-19.19%+56.56%SLSSELLAS Life Sciences Group0.00%-4.11%-4.11%+37.25%-16.67%TILInstil Bio0.00%-4.04%+4.11%-7.65%-10.99%Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourselfMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVCRDiversicare Healthcare ServicesN/AN/AN/AN/AN/AN/AN/AN/ANVNOenVVeno Medical0.093 of 5 stars0.01.00.00.02.01.70.6SLSSELLAS Life Sciences Group1.1614 of 5 stars3.51.00.00.02.80.00.6TILInstil Bio3.6036 of 5 stars3.35.00.00.03.93.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVCRDiversicare Healthcare ServicesN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/ASLSSELLAS Life Sciences Group3.00Buy$3.00114.29% UpsideTILInstil Bio2.67Moderate Buy$25.00126.45% UpsideCurrent Analyst RatingsLatest DVCR, TIL, SLS, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2024TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/13/2024TILInstil BioRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $32.004/12/2024TILInstil BioJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/25/2024TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00(Data available from 5/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVCRDiversicare Healthcare Services$475.72M0.15$5.87 per share1.72($4.57) per share-2.21NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/ASLSSELLAS Life Sciences Group$1M80.86N/AN/A($0.25) per share-5.60TILInstil BioN/AN/AN/AN/A$34.72 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVCRDiversicare Healthcare Services$5.16M$0.3628.03∞N/A0.53%-15.01%1.05%N/ANVNOenVVeno Medical-$23.52M-$1.66N/AN/AN/AN/A-62.17%-57.58%7/29/2024 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$1.10N/AN/AN/AN/A-5,258.30%-249.95%8/8/2024 (Estimated)TILInstil Bio-$156.09M-$18.93N/AN/AN/AN/A-51.27%-35.73%8/12/2024 (Estimated)Latest DVCR, TIL, SLS, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024Q1 2024NVNOenVVeno MedicalN/A-$0.31-$0.31-$0.31N/AN/A3/28/2024Q4 2023SLSSELLAS Life Sciences GroupN/A-$0.25-$0.25-$0.25N/AN/A3/21/2024Q4 2023TILInstil BioN/A-$1.99-$1.99-$1.99N/AN/A2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVCRDiversicare Healthcare ServicesN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVCRDiversicare Healthcare ServicesN/A0.830.83NVNOenVVeno MedicalN/A29.0829.08SLSSELLAS Life Sciences GroupN/A1.491.49TILInstil Bio0.4014.1914.19OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVCRDiversicare Healthcare Services33.14%NVNOenVVeno Medical34.71%SLSSELLAS Life Sciences Group17.38%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipDVCRDiversicare Healthcare Services34.30%NVNOenVVeno Medical17.00%SLSSELLAS Life Sciences Group1.60%TILInstil Bio46.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDVCRDiversicare Healthcare Services3,7506.95 million4.57 millionNot OptionableNVNOenVVeno Medical1913.33 million11.06 millionOptionableSLSSELLAS Life Sciences Group1757.76 million56.83 millionNot OptionableTILInstil Bio496.50 million3.48 millionOptionableDVCR, TIL, SLS, and NVNO HeadlinesRecent News About These CompaniesMay 23, 2024 | markets.businessinsider.comPremier Health Reports 2024 Second Quarter ResultsMay 10, 2024 | investorplace.comTIL Stock Earnings: Instil Bio Misses EPS for Q1 2024May 10, 2024 | markets.businessinsider.comInstil Bio, Inc. Q1 Loss DecreasesMay 10, 2024 | finance.yahoo.comInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | globenewswire.comInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 1, 2024 | finance.yahoo.comBiO-LiFE Herbalmeds Launches The Power of Sleep Campaign To Encourage Malaysians To Sleep Well and Stay HealthyApril 26, 2024 | lifestyleasia.comJentle Salon: BLACKPINK Jennie and Gentle Monster’s third collab will get a pop-up at MBSApril 21, 2024 | msn.comThis actor once saw father saved murder accused, qualified for Olympics, then became Bollywood's top villain, died at...April 19, 2024 | dailypioneer.comSustainability through global collaborationApril 17, 2024 | msn.comInstil Bio (TIL) Price Target Decreased by 23.15% to 28.22April 12, 2024 | msn.comJefferies cuts Instil Bio to hold, cites drug discontinuationMarch 29, 2024 | research-live.comLearning from nature, investing in people and ownership culture can future-proof the insight functionMarch 27, 2024 | zacks.comWhat Makes Instil Bio (TIL) a New Buy StockMarch 22, 2024 | seekingalpha.comInstil Bio Non-GAAP EPS of -$1.26 beats by $2.14March 21, 2024 | globenewswire.comInstil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 14, 2024 | forbesindia.comUK Treasury to overhaul crypto regulations to strengthen AML measuresMarch 12, 2024 | ft.comA Very Private School — Charles Spencer’s privileged but painful educationMarch 11, 2024 | theguardian.comJon Cruddas: ‘Labour has to rediscover its moral purpose’February 24, 2024 | financialexpress.comJunglee Poker launches Apne Type Ke Log campaign featuring Anil KapoorFebruary 24, 2024 | benzinga.comInstil Bio Stock (NASDAQ:TIL) Dividends: History, Yield and DatesNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesWhat Bulls and Bears May Be Getting Wrong about SOFI StockApril 29, 2024 12:29 PMView What Bulls and Bears May Be Getting Wrong about SOFI Stock3 Affordable Stocks That Won’t Stay Down Much LongerMay 13, 2024 9:12 AMView 3 Affordable Stocks That Won’t Stay Down Much LongerAnalysts Still Want Double-Digit Upside Out of Applied MaterialsMay 17, 2024 9:12 AMView Analysts Still Want Double-Digit Upside Out of Applied Materials3 CEO-Led Turnaround Stocks You Can Still Buy May 6, 2024 8:55 AMView 3 CEO-Led Turnaround Stocks You Can Still Buy Rocket Lab Stock Drops but Could Still Launch HigherMay 13, 2024 7:30 AMView Rocket Lab Stock Drops but Could Still Launch HigherAll HeadlinesCompany DescriptionsDiversicare Healthcare ServicesOTCMKTS:DVCRDiversicare Healthcare Services, Inc. provides post-acute care services. The firm offers services to patients and residents including skilled nursing, ancillary health care services and assisted living. It also provides long-term care centres and rehabilitative, nutritional, respiratory and other specialized ancillary services. The company was founded in 1994 and is headquartered in Brentwood, TN.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. SELLAS Life Sciences GroupNASDAQ:SLSSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Instil BioNASDAQ:TILInstil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.